Missouri Trial Began Over Roundup Cancer Allegations
Three cancer patients are suing Monsanto, alleging the company failed to test its Roundup weed killer for safety.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you trust that large manufacturers sufficiently test their products for health risks before selling them?
A Missouri court has commenced a trial involving three cancer patients who allege that Roundup caused their non-Hodgkin lymphoma. This case is part of a massive legal landscape involving approximately 65,000 pending claims against Bayer, the company that acquired Roundup manufacturer Monsanto in 2018.
Why it matters
The outcome of this trial reflects the ongoing struggle to reconcile regulatory safety conclusions with legal claims of product liability regarding glyphosate. For many, these cases raise questions about the long-term health implications of common chemical exposures in residential and professional settings.
This trial centers on three individuals diagnosed with non-Hodgkin lymphoma, part of a larger cohort of approximately 65,000 cases currently moving through the U.S. legal system. While a $7.25 billion settlement proposal remains under review, the scientific debate over glyphosate safety persists.
The players
Bayer
A global pharmaceutical and life sciences company that produces various healthcare treatments and agrochemicals, including the Roundup line.
Monsanto
The original manufacturer of Roundup that was acquired by Bayer in 2018.
Theresa Aretino
A plaintiff in the current Missouri court case who developed non-Hodgkin lymphoma.
Betty Larkin
A plaintiff in the current Missouri court case who developed non-Hodgkin lymphoma.
Cynthia Fernandez
A plaintiff in the current Missouri court case who developed non-Hodgkin lymphoma and passed away before the trial commenced.
The details
Plaintiffs argue that Monsanto defectively designed Roundup and failed to conduct necessary safety testing prior to sale. Conversely, Bayer maintains that decades of regulatory studies support the safety of glyphosate. The court proceedings, which are broadcast via the Courtroom View Network, highlight the intense disagreement between legal arguments concerning product design and existing regulatory data.
Timeline
2018: Bayer acquired Monsanto.
June 2026: The U.S. Supreme Court issued a ruling on warning label lawsuits.
September 29, 2026: Trial proceedings began in a Missouri court.
End of 2026: The EPA is expected to complete its re-evaluation of glyphosate.
Health Landscape
The current litigation follows a pattern set by the U.S. Supreme Court's 2026 ruling on warning label lawsuits, which established limits on specific legal claims against manufacturers. This trial highlights the ongoing tension between federal regulatory standards and state-level product liability actions.
If you are concerned about potential health risks from chemical exposures, discuss your medical history and environmental history with your physician. They can help you identify relevant health screenings and provide guidance on minimizing your personal exposure risks.
The takeaway
This case highlights the complexities of assessing long-term health risks associated with chemical products. Individuals should continue to focus on maintaining regular health checkups and discussing specific environmental concerns with their primary care provider.
Further reading
For broader information on disease risks and prevention, visit Cancer.
Live Poll
Do you trust that large manufacturers sufficiently test their products for health risks before selling them?
